A fundamental relationship between hydrophobic properties and biological activity for the duocarmycin class of DNA-alkylating antitumor drugs: Hydrophobic-binding-driven bonding

Journal of Medicinal Chemistry

Volumn 56, Issue 17, 2013, Pages 6845-6857

  Wolfe, Amanda L ^a   Duncan, Katharine K ^a   Lajiness, James P ^a   Zhu, Kaicheng ^a   Duerfeldt, Adam S ^a   Boger, Dale L ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DUOCARMYCIN SA; ETHYLENE GLYCOL; INDOLE; WATER;

ANIMAL CELL; ARTICLE; BIOLOGICAL ACTIVITY; CELL GROWTH; DNA ALKYLATION; DNA BINDING; DRUG SYNTHESIS; GROWTH INHIBITION; HYDROPHOBICITY; IC 50; NONHUMAN; SOLUBILITY;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BINDING SITES; CELL LINE, TUMOR; DNA; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; INDOLES; INHIBITORY CONCENTRATION 50; MAGNETIC RESONANCE SPECTROSCOPY; MICE; PYRROLES; SOLUBILITY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 84884221375     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400665c     Document Type: Article

References (100)

1. Martin, D. G.; Biles, C.; Gerpheide, S. A.; Hanka, L. J.; Krueger, W. C.; McGovren, J. P.; Mizsak, S. A.; Neil, G. L.; Stewart, J. C.; Visser, J. CC-1065 (NSC 298223), a Potent New Antitumor Agent: Improved Production and Isolation, Characterization and Antitumor Activity J. Antibiot. 1981, 34, 1119-1125
2. Ichimura, M.; Ogawa, T.; Takahashi, K.; Kobayashi, E.; Kawamoto, I.; Yasuzawa, T.; Takahashi, I.; Nakano, H. Duocarmycin SA, a New Antitumor Antibiotic from Streptomyces sp J. Antibiot. 1990, 43, 1037-1038
3. Takahashi, I.; Takahashi, K.; Ichimura, M.; Morimoto, M.; Asano, K.; Kawamoto, I.; Tomita, F.; Nakano, H. Duocarmycin, a New Antitumor Antibiotic from Streptomyces J. Antibiot. 1988, 41, 1915-1917
4. Igarashi, Y.; Futamata, K.; Fujita, T.; Sekine, A.; Senda, H.; Naoki, H.; Furumai, T. Yatakemycin, a Novel Antifungal Antibiotic Produced by Streptomyces sp. TP-A0356 J. Antibiot. 2003, 56, 107-113
5. Boger, D. L.; Johnson, D. S.; Yun, W. (+)- and ent -(-)-Duocarmycin SA and (+)- and ent -(-)- N -Boc-DSA DNA Alkylation Properties. Alkylation Site Models That Accommodate the Offset AT-Rich Adenine N3 Alkylation Selectivity of the Enantiomeric Agents J. Am. Chem. Soc. 1994, 116, 1635-1656
6. Parrish, J. P.; Kastrinsky, D. B.; Wolkenberg, S. E.; Igarashi, Y.; Boger, D. L. DNA Alkylation Properties of Yatakemycin J. Am. Chem. Soc. 2003, 125, 10971-10976
7. Trzupek, J. D.; Gottesfeld, J. M.; Boger, D. L. Alkylation of Duplex DNA in Nucleosome Core Particles by Duocarmycin SA and Yatakemycin Nat. Chem. Biol. 2006, 2, 79-82
8. Tichenor, M. S.; MacMillan, K. S.; Trzupek, J. D.; Rayl, T. J.; Hwang, I.; Boger, D. L. Systematic Exploration of the Structural Features of Yatakemycin Impacting DNA Alkylation and Biological Activity J. Am. Chem. Soc. 2007, 129, 10858-10869
9. Hurley, L. H.; Lee, C.-S.; McGovren, J. P.; Warpehoski, M. A.; Mitchell, M. A.; Kelly, R. C.; Aristoff, P. A. Molecular Basis for Sequence-Specific DNA Alkylation by CC-1065 Biochemistry 1988, 27, 3886-3892
10. Hurley, L. H.; Warpehoski, M. A.; Lee, C.-S.; McGovren, J. P.; Scahill, T. A.; Kelly, R. C.; Mitchell, M. A.; Wicnienski, N. A.; Gebhard, I.; Johnson, P. D.; Bradford, V. S. Sequence Specificity of DNA Alkylation by the Unnatural Enantiomer of CC-1065 and Its Synthetic Analogues J. Am. Chem. Soc. 1990, 112, 4633-4649
11. Boger, D. L.; Johnson, D. S.; Yun, W.; Tarby, C. M. Molecular Basis for Sequence Selective DNA Alkylation by (+)- and ent -(-)-CC-1065 and Related Agents: Alkylation Site Models That Accommodate the Offset AT-Rich Adenine N3 Alkylation Selectivity Bioorg. Med. Chem. 1994, 2, 115-135
12. 3. Preparation of Key Partial Structures and Definition of an Additional Functional Role of the CC-1065 Central and Right-Hand Subunits J. Am. Chem. Soc. 1990, 112, 4623-4632
13. Boger, D. L.; Ishizaki, T.; Zarrinmayeh, H.; Munk, S. A.; Kitos, P. A.; Suntornwat, O. Duocarmycin-Pyrindamycin DNA Alkylation Properties and Identification, Synthesis, and Evaluation of Agents Incorporating the Pharmacophore of the Duocarmycin-Pyrindamycin Alkylation Subunit. Identification of the CC-1065 Duocarmycin Common Pharmacophore J. Am. Chem. Soc. 1990, 112, 8961-8971
14. Boger, D. L.; Ishizaki, T.; Zarrinmayeh, H. Isolation and Characterization of the Duocarmycin-Adenine DNA Adduct J. Am. Chem. Soc. 1991, 113, 6645-6649
15. Boger, D. L.; Yun, W.; Terashima, S.; Fukuda, Y.; Nakatani, K.; Kitos, P. A.; Jin, Q. DNA Alkylation Properties of the Duocarmycins: (+)-Duocarmycin A, epi -(+)-Duocarmycin A, ent -(-)-Duocarmycin A and epi, ent -(-)-Duocarmycin A Bioorg. Med. Chem. Lett. 1992, 2, 759-765
16. Boger, D. L.; Johnson, D. S. CC-1065 and the Duocarmycins: Understanding Their Biological Function through Mechanistic Studies Angew. Chem., Int. Ed. Engl. 1996, 35, 1438-1474
17. Boger, D. L. The Duocarmycins: Synthetic and Mechanistic Studies Acc. Chem. Res. 1995, 28, 20-29
18. Boger, D. L.; Johnson, D. S. CC-1065 and the Duocarmycins: Unraveling the Keys to a New Class of Naturally Derived DNA Alkylating Agents Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 3642-3649
19. Tichenor, M. S.; Boger, D. L. Yatakemycin: Total Synthesis, DNA Alkylation, and Biological Properties Nat. Prod. Rep. 2008, 25, 220-226
20. MacMillan, K. S.; Boger, D. L. Fundamental Relationships between Structure, Reactivity, and Biological Activity for the Duocarmycins and CC-1065 J. Med. Chem. 2009, 52, 5771-5780
21. Searcey, M. Duocarmycins: Nature's Prodrugs? Curr. Pharm. Des. 2002, 8, 1375-1389
22. Boger, D. L.; Coleman, R. S. Total Synthesis of (+)-CC-1065 and ent -(-)-CC-1065 J. Am. Chem. Soc. 1988, 110, 1321-1323
23. 2 [(±)-(3b R*,4a S*), (+)-(3b R,4a S), and (-)-(3b S,4a R)-Deoxy-CC-1065] J. Am. Chem. Soc. 1988, 110, 4796-4807
24. Boger, D. L.; Machiya, K. Total Synthesis of (+)-Duocarmycin SA J. Am. Chem. Soc. 1992, 114, 10056-10058
25. Boger, D. L.; Machiya, K.; Hertzog, D. L.; Kitos, P. A.; Holmes, D. Total Synthesis and Preliminary Evaluation of (+)- and ent -(-)-Duocarmycin SA J. Am. Chem. Soc. 1993, 115, 9025-9036
26. Boger, D. L.; Yun, W. CBI-TMI: Synthesis and Evaluation of a Key Analog of the Duocarmycins. Validation of a Direct Relationship between Chemical Solvolytic Stability and Cytotoxic Potency and Confirmation of the Structural Features Responsible for the Distinguishing Behavior of Enantiomeric Pairs of Agents J. Am. Chem. Soc. 1994, 116, 7996-8006
27. Boger, D. L.; McKie, J. A.; Nishi, T.; Ogiku, T. Enantioselective Total Synthesis of (+)-Duocarmycin A, epi -(+)-Duocarmycin A, and Their Unnatural Enantiomers J. Am. Chem. Soc. 1996, 118, 2301-2302
28. Boger, D. L.; McKie, J. A.; Nishi, T.; Ogiku, T. Total Synthesis of (+)-Duocarmycin A, epi -(+)-Duocarmycin A and Their Unnatural Enantiomers: Assessment of Chemical and Biological Properties J. Am. Chem. Soc. 1997, 119, 311-325
29. Tichenor, M. S.; Trzupek, J. D.; Kastrinsky, D. B.; Shiga, F.; Hwang, I.; Boger, D. L. Asymmetric Total Synthesis of (+)- and ent -(-)-Yatakemycin and Duocarmycin SA. Evaluation of Yatakemycin Key Partial Structures and Its Unnatural Enantiomer J. Am. Chem. Soc. 2006, 128, 15683-15696
30. MacMillan, K. S.; Nguyen, T.; Hwang, I.; Boger, D. L. Total Synthesis and Evaluation of iso -Duocarmycin SA and iso -Yatakemycin J. Am. Chem. Soc. 2009, 131, 1187-1194
31. Boger, D. L.; Boyce, C. E.; Garbaccio, R. M.; Goldberg, J. A. CC-1065 and the Duocarmycins: Synthetic Studies Chem. Rev. 1997, 97, 787-828
32. Boger, D. L.; Hertzog, D. L.; Bollinger, B.; Johnson, D. S.; Cai, H.; Goldberg, J.; Turnbull, P. Duocarmycin SA Shortened, Simplified, and Extended Agents: A Systematic Examination of the Role of the DNA Binding Subunit J. Am. Chem. Soc. 1997, 119, 4977-4986
33. Boger, D. L.; Bollinger, B.; Hertzog, D. L.; Johnson, D. S.; Cai, H.; Mesini, P.; Garbaccio, R. M.; Jin, Q.; Kitos, P. A. Reversed and Sandwiched Analogs of Duocarmycin SA: Establishment of the Origin of the Sequence-Selective Alkylation of DNA and New Insights into the Source of Catalysis J. Am. Chem. Soc. 1997, 119, 4987-4998
34. Boger, D. L.; Garbaccio, R. M. Catalysis of the CC-1065 and Duocarmycin DNA Alkylation Reaction: DNA Binding Induced Conformational Change in the Agent Results in Activation Bioorg. Med. Chem. 1997, 5, 263-276
35. Boger, D. L.; Turnbull, P. Synthesis and Evaluation of a Carbocyclic Analogue of the CC-1065 and Duocarmycin Alkylation Subunits: Role of the Vinylogous Amide and Implications on DNA Alkylation Catalysis J. Org. Chem. 1998, 63, 8004-8011
36. Boger, D. L.; Garbaccio, R. M. Shape-Dependent Catalysis: Insights into the Source of Catalysis for the CC-1065 and Duocarmycin DNA Alkylation Reaction Acc. Chem. Res. 1999, 32, 1043-1052
37. Wolkenberg, S. E.; Boger, D. L. Mechanisms of in Situ Activation for DNA-Targeting Antitumor Agents Chem. Rev. 2002, 102, 2477-2495
38. Boger, D. L.; Turnbull, P. Synthesis and Evaluation of CC-1065 and Duocarmycin Analogs Incorporating the 1,2,3,4,11,11a-Hexahydrocyclopropa[ c ]naphtho[2,1- b ]azepin-6-one (CNA) Alkylation Subunit: Structural Features That Govern Reactivity and Reaction Regioselectivity J. Org. Chem. 1997, 62, 5849-5863
39. Aristoff, P. A. CC-1065 Analogs: Sequence Specific DNA-Alkylating Antitumor Agents Adv. Med. Chem. 1993, 2, 67-110
40. Kobayashi, E.; Okamoto, A.; Asada, M.; Okabe, M.; Nagamura, S.; Asai, A.; Saito, H.; Gomi, K.; Hirata, T. Characteristics of Antitumor Activity of KW-2189, a Novel Water-Soluble Derivative of Duocarmycin, against Murine and Human Tumors Cancer Res. 1994, 54, 2404-2410
41. Amishiro, N.; Nagamura, S.; Kobayashi, E.; Gomi, K.; Saito, H. New Water-Soluble Duocarmycin Derivatives: Synthesis and Antitumor Activity of A-Ring Pyrrole Compounds Bearing β-Heteroarylacryloyl Groups J. Med. Chem. 1999, 42, 669-676
42. Nagamura, S.; Asai, A.; Kanda, Y.; Kobayashi, E.; Gomi, K.; Saito, H. Synthesis and Antitumor Activity of Duocarmycin Derivatives: Modification of Segment A of Duocarmycin B2 Chem. Pharm. Bull. 1996, 44, 1723-1730
43. Nagamura, S.; Kanda, Y.; Kobayashi, E.; Gomi, K.; Saito, H. Synthesis and Antitumor Activity of Duocarmycin Derivatives Chem. Pharm. Bull. 1995, 43, 1530-1535
44. Boger, D. L.; Boyce, C. W.; Garbaccio, R. M.; Searcey, M.; Jin, Q. CBI Prodrug Analogs of CC-1065 and the Duocarmycins Synthesis 1999, 1505-1509
45. Tietze, L. F.; Schuster, H. J.; Schmuck, K.; Schuberth, I.; Alves, F. Duocarmycin-Based Prodrugs for Cancer Prodrug Monotherapy Bioorg. Med. Chem. 2008, 16, 6312-6318
46. Tietze, L. F.; Lieb, M.; Herzig, T.; Haunert, F.; Schuberth, I. Strategy for Tumor-Selective Chemotherapy by Enzymatic Liberation of seco -Duocarmycin SA Derivatives from Nontoxic Prodrugs Bioorg. Med. Chem. 2001, 9, 1929-1939
47. Li, L. S.; Sinha, S. C. Studies toward Duocarmycin Prodrugs for the Antibody Prodrug Therapy Approach Tetrahedron Lett. 2009, 50, 2932-2935
48. Asai, A.; Nagamura, S.; Kobayashi, E.; Gomi, K.; Saito, H. Synthesis and Antitumor Activity of Water-Soluble Duocarmycin B1 Prodrugs Bioorg. Med. Chem. Lett. 1999, 9, 2995-2998
49. Jin, W.; Trzupek, J. D.; Rayl, T. J.; Broward, M. A.; Vielhauer, G. A.; Weir, S. J.; Hwang, I.; Boger, D. L. A Unique Class of Duocarmycin and CC-1065 Analogues Subject to Reductive Activation J. Am. Chem. Soc. 2007, 129, 15391-15397
50. Lajiness, J. P.; Robertson, W. M.; Dunwiddie, I.; Broward, M. A.; Vielhauer, G. A.; Weir, S. J.; Boger, D. L. Design, Synthesis, and Evaluation of Duocarmycin O -Amino Phenol Prodrugs Subject to Tunable Reductive Activation J. Med. Chem. 2010, 53, 7731-7738
51. Wolfe, A. L.; Duncan, K. K.; Parelkar, N.; Weir, S. J.; Vielhauer, G. A.; Boger, D. L. A Novel, Unusually Efficacious Duocarmycin Carbamate Prodrug That Releases No Residual Byproduct J. Med. Chem. 2012, 55, 5878-5886
52. Pors, K.; Loadman, P. M.; Shnyder, S. D.; Sutherland, M.; Sheldrake, H. M.; Guino, M.; Kiakos, K.; Hartley, J. A.; Searcey, M.; Patterson, L. H. Modification of the Duocarmycin Pharmacophore Enables CYP1A1 Targeting for Biological Activity Chem. Commun. 2011, 47, 12062-12064
53. Lillo, A. M.; Sun, C.; Gao, C.; Ditzel, H.; Parrish, J. P.; Gauss, C.-M.; Moss, J.; Felding-Habermann, B.; Wirsching, P.; Boger, D. L.; Janda, K. D. A Human Single-Chain Antibody Specific for Integrin α3β1 Capable of Cell Internalization and Delivery of Antitumor Agents Chem. Biol. 2004, 11, 897-906
54. Goldmacher, V. S.; Kovtun, Y. V. Antibody-Drug Conjugates: Using Monoclonal Antibodies for Delivery of Cytotoxic Payloads to Cancer Cells Ther. Delivery 2011, 2, 397-416
55. Ducry, L.; Stump, B. Antibody-Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies Bioconjugate Chem. 2010, 21, 5-13
56. Zhao, R. H.; Erickson, H. K.; Leece, B. A.; Reid, E. E.; Goldmacher, V. S.; Lambert, J. M.; Chari, R. V. J. Synthesis and Biological Evaluation of Antibody Conjugates of Phosphate Prodrugs of Cytotoxic DNA Alkylators for the Targeted Treatment of Cancer J. Med. Chem. 2012, 55, 766-782
57. Eis, P. S.; Smith, J. A.; Rydzewski, J. M.; Case, D. A.; Boger, D. L.; Chazin, W. J. High Resolution Solution Structure of a DNA Duplex Alkylated by the Antitumor Agent Duocarmycin SA J. Mol. Biol. 1997, 272, 237-252
58. Schnell, J. R.; Ketchem, R. R.; Boger, D. L.; Chazin, W. J. Binding-Induced Activation of DNA Alkylation by Duocarmycin SA: Insights from the Structure of an Indole Derivative-DNA Adduct J. Am. Chem. Soc. 1999, 121, 5645-5652
59. Smith, J. A.; Bifulco, G.; Case, D. A.; Boger, D. L.; Gomez-Paloma, L.; Chazin, W. J. The Structural Basis for in Situ Activation of DNA Alkylation by Duocarmycin SA J. Mol. Biol. 2000, 300, 1195-1204
60. Bassarello, C.; Cimino, P.; Bifulco, G.; Boger, D. L.; Smith, J. A.; Chazin, W. J.; Paloma, L. G. NMR Structure of the (+)-CPI-indole/d(GACTAATTGAC)- d(GTCAATTAGTC) Covalent Complex ChemBioChem 2003, 4, 1188-1193
61. Robertson, W. M.; Kastrinsky, D. B.; Hwang, I.; Boger, D. L. Synthesis and Evaluation of a Series of C5′-Substituted Duocarmycin SA Analogs Bioorg. Med. Chem. Lett. 2010, 20, 2722-2725
62. Tse, W. C.; Boger, D. L. Sequence-Selective DNA Recognition: Natural Products and Nature's Lessons Chem. Biol. 2004, 11, 1607-1617
63. Ouchi, M.; Inoue, Y.; Liu, Y.; Nagamune, S.; Nakamura, S.; Wada, K.; Hakaushi, T. Convenient and Efficient Tosylation of Oligoethylene Glycols and the Related Alcohols in Tetrahydrofuran-Water in the Presence of Sodium Hydroxide Bull. Chem. Soc. Jpn. 1990, 63, 1260-1262
64. Boger, D. L.; Ishizaki, T.; Zarrinmayeh, H.; Kitos, P. A.; Suntornwat, O. Synthesis and Preliminary Evaluation of Agents Incorporating the Pharmacophore of the Duocarmycin/Pyrindamycin Alkylation Subunit: Identification of the CC-1065/Duocarmycin Common Pharmacophore J. Org. Chem. 1990, 55, 4499-4502
65. Boger, D. L.; Coleman, R. S. Diels-Alder Reactions of Heterocyclic Azadienes: Total Synthesis of PDE I, PDE II, and PDE I Dimer Methyl Ester J. Am. Chem. Soc. 1987, 109, 2717-2727
66. Boger, D. L.; Coleman, R. S.; Invergo, B. J. Studies on the Total Synthesis of CC-1065: Preparation of a Synthetic Simplified 3-Carbamoyl-1,2- dihydro-3 H -pyrrolo[3,2- e ]indole Dimer/Trimer/Tetramer (CDPI Dimer/Trimer/Tetramer) and Development of Methodology for PDE-I Dimer Methyl Ester Formation J. Org. Chem. 1987, 52, 1521-1530
67. Tichenor, M. S.; Kastrinsky, D. B.; Boger, D. L. Total Synthesis, Structure Revision, and Absolute Configuration of (+)-Yatakemycin J. Am. Chem. Soc. 2004, 126, 8396-8398
68. 32-End-Labeled Double-Stranded DNA for Binding Studies. Development of a Protocol for Examination of Functional Features of (+)-CC-1065 and the Duocarmycins That Contribute to Their Sequence-Selective DNA Alkylation Properties Tetrahedron 1991, 47, 2661-2682
69. Boger, D. L.; Munk, S. A. DNA Alkylation Properties of Enhanced Functional Analogs of CC-1065 Incorporating the 1,2,9,9a-Tetrahydrocyclopropa[1, 2- c ]benz[1,2- e ]indol-4-one (CBI) Alkylation Subunit J. Am. Chem. Soc. 1992, 114, 5487-5496
70. Schneider, C. A.; Rasband, W. S.; Eliceiri, K. W. NIH Image to ImageJ: 25 Years of Image Analysis Nat. Methods 2012, 9, 671-675
71. Boger, D. L.; Fink, B. E.; Brunette, S. R.; Tse, W. C.; Hedrick, M. P. A Simple, High Resolution Method for Establishing DNA Binding Affinity and Sequence Selectivity J. Am. Chem. Soc. 2001, 123, 5878-5891
72. Tse, W. C.; Boger, D. L. A Fluorescent Intercalator Displacement (FID) Assay for Establishing DNA Binding Selectivity and Affinity Acc. Chem. Res. 2004, 37, 61-69
73. Boger, D. L.; Fink, B. E.; Hedrick, M. P. Total Synthesis of Distamycin A and 2640 Analogues: Solution-Phase Combinatorial Approach to the Discovery of New, Bioactive DNA Binding Agents and Development of a Rapid, High-Throughput Screen for Determining Relative DNA Binding Affinity or DNA Binding Sequence Selectivity J. Am. Chem. Soc. 2000, 122, 6382-6394
74. Boger, D. L.; Tse, W. C. Thiazole Orange as the Fluorescent Intercalator in a High Resolution FID Assay for Determining DNA Binding Affinity and Sequence Selectivity of Small Molecules Bioorg. Med. Chem. 2001, 9, 2511-2518
75. Yeung, B. K. S.; Tse, W. C.; Boger, D. L. Determination of Binding Affinities of Triplex Forming Oligonucleotides Using a Fluorescent Intercalator Displacement (FID) Assay Bioorg. Med. Chem. Lett. 2003, 13, 3801-3804
76. Ham, Y.-W.; Tse, W. C.; Boger, D. L. High Resolution Assessment of Protein-DNA Binding Affinity and Selectivity Utilizing a Fluorescent Intercalator Displacement (FID) Assay Bioorg. Med. Chem. Lett. 2003, 13, 3805-3807
77. Tse, W. C.; Ishii, T.; Boger, D. L. Comprehensive High Resolution Analysis of Hairpin Polyamides Utilizing a Fluorescent Intercalator Displacement (FID) Assay Bioorg. Med. Chem. 2003, 11, 4479-4486
78. Woods, C. R.; Ishii, T.; Wu, B.; Bair, K. W.; Boger, D. L. Hairpin versus Extended DNA Binding of a Substituted β-Alanine Linked Polyamide J. Am. Chem. Soc. 2002, 124, 2148-2152
79. Woods, C. R.; Ishii, T.; Boger, D. L. Synthesis and DNA Binding Properties of Iminodiacetic Acid-Linked Polyamides: Characterization of Cooperative Extended 2:1 Side-by-Side Parallel Binding J. Am. Chem. Soc. 2002, 124, 10676-10682
80. Lessen, P. D.; Springthorpe, B. The Influence of Drug-like Concepts on Decision-Making in Medicinal Chemistry Nat. Rev. Drug Discovery 2007, 6, 881-890
81. Edwards, M. P.; Price, D. A. Role of Physicochemical Properties and Ligand Lipophilicity Efficiency in Addressing Drug Safety Risks Annu. Rep. Med. Chem. 2010, 45, 381-391
82. Mitchell, R. C. Hydrogen Bonding. 32. An Analysis of Water-Octanol and Water-Alkane Partitioning and the ΔLogP Parameter of Seiler J. Pharm. Sci. 1994, 83, 1085-1100
83. A cLogP value of approximately 2 or lower is often consistent with reasonable in vivo clearance, solubility, and protein binding. High-LiPE compounds should outperform low-LiPE compounds, as these will be compromised by reduced potency or increased lipophilicity. A recent analysis of animal safety studies revealed an increased risk of adverse outcome for compounds with cLogP > 3. While achievable LiPE values are target- and series-specific, compounds with LiPE > 5 are usually considered highly optimized.
84. 5 range (2 vs 10e). See: Kansy, M.; Senner, F.; Gubernator, K. Physicochemical High Throughput Screening: Parallel Artificial Membrane Permeability Assay in the Description of Passive Absorption Processes J. Med. Chem. 1998, 41, 1007-1010
85. Boger, D. L.; Coleman, R. S.; Invergo, B. J.; Zarrinmayeh, H.; Kitos, P. A.; Thompson, S. C.; Leong, T.; McLaughlin, L. W. A Demonstration of the Intrinsic Importance of Stabilizing Hydrophobic Binding and Non-Covalent van der Waals Contacts Dominant in the Non-Covalent CC-1065/B-DNA Binding Chem.-Biol. Interact. 1990, 73, 29-52
86. Boger, D. L.; Yun, W. Reversibility of the Duocarmycin A and SA DNA Alkylation Reaction J. Am. Chem. Soc. 1993, 115, 9872-9873
87. Boger, D. L.; Zarrinmayeh, H.; Munk, S. A.; Kitos, P. A.; Suntornwat, O. Demonstration of a Pronounced Effect of Noncovalent Binding Selectivity on the (+)-CC-1065 DNA Alkylation and Identification of the Pharmacophore of the Alkylation Subunit Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 1431-1435
88. Boger, D. L.; Munk, S. A.; Zarrinmayeh, H. (+)-CC-1065 DNA Alkylation: Key Studies Demonstrating a Noncovalent Binding Selectivity Contribution to the Alkylation Selectivity J. Am. Chem. Soc. 1991, 113, 3980-3983
89. Boger, D. L.; Johnson, D. S. Second Definitive Test of Proposed Models for the Origin of the CC-1065 and Duocarmycin DNA Alkylation Selectivity J. Am. Chem. Soc. 1995, 117, 1443-1444
90. Boger, D. L.; Zhou, J.; Cai, H. Demonstration and Definition of the Noncovalent Binding Selectivity of Agents Related to CC-1065 by an Affinity Cleavage Agent: Noncovalent Binding Coincidental with Alkylation Bioorg. Med. Chem. 1996, 4, 859-868
91. 2: CC-1065 Functional Analogs Incorporating the Parent 1,2,7,7a- Tetrahydrocyclopropa[1,2- c ]indol-4-one (CI) Left-Hand Subunit J. Am. Chem. Soc. 1990, 112, 5230-5240
92. Boger, D. L.; Mesini, P. Design, Synthesis, and Evaluation of CC-1065 and Duocarmycin Analogs Incorporating the 2,3,10,10a-Tetrahydro-1 H -cyclopropa[ d ]benzo[ f ]quinol-5-one (CBQ) Alkylation Subunit: Identification and Structural Origin of Subtle Stereoelectronic Features That Govern Reactivity and Regioselectivity J. Am. Chem. Soc. 1994, 116, 11335-11348
93. Boger, D. L.; Santillan, A., Jr.; Searcey, M.; Brunette, S. R.; Wolkenberg, S. E.; Hedrick, M. P.; Jin, Q. Synthesis and Evaluation of 1,2,8,8a-Tetrahydrocyclopropa[ c ]pyrrolo[3,2- e ]indol-4(5 H)-one, the Parent Alkylation Subunit of CC-1065 and the Duocarmycins: Impact of the Alkylation Subunit Substituents and Its Implications for DNA Alkylation Catalysis J. Org. Chem. 2000, 65, 4101-4111
94. Boger, D. L.; Stauffer, F.; Hedrick, M. P. Substituent Effects within the DNA Binding Subunit of CBI Analogues of the Duocarmycins and CC-1065 Bioorg. Med. Chem. Lett. 2001, 11, 2021-2024
95. Parrish, J. P.; Hughes, T. V.; Hwang, I.; Boger, D. L. Establishing the Parabolic Relationship between Reactivity and Activity for Derivatives and Analogues of the Duocarmycin and CC-1065 Alkylation Subunits J. Am. Chem. Soc. 2004, 126, 80-81
96. 2: Enhanced Functional Analogs of (+)-CC-1065. A Critical Appraisal of the Proposed Relationship between Electrophile Reactivity, DNA Binding Properties, and Cytotoxic Potency Tetrahedron Lett. 1990, 31, 793-796
97. 2: An Enhanced Functional Analog of (+)-CC-1065 Bioorg. Med. Chem. Lett. 1991, 1, 115-120
98. Boger, D. L.; Munk, S. A.; Ishizaki, T. The (+)-CC-1065 DNA Alkylation: Observation of an Unexpected Relationship between Cyclopropane Electrophile Reactivity and the Efficiency of DNA Alkylation J. Am. Chem. Soc. 1991, 113, 2779-2780
99. Boger, D. L.; Yun, W. Role of the CC-1065 and Duocarmycin N2 Substituent: Validation of a Direct Relationship between Solvolysis Chemical Stability and in Vitro Biological Potency J. Am. Chem. Soc. 1994, 116, 5523-5524
100. Tichenor, M. S.; MacMillan, K. S.; Stover, J. S.; Wolkenberg, S. E.; Pavani, M. G.; Zanella, L.; Zaid, A. N.; Spalluto, G.; Rayl, T. J.; Hwang, I.; Baraldi, P. G.; Boger, D. L. Rational Design, Synthesis, and Evaluation of Key Analogues of CC-1065 and the Duocarmycins J. Am. Chem. Soc. 2007, 129, 14092-14099